Your browser doesn't support javascript.
loading
Prevalence and clinical implications of the TP53 pR337H mutation in Brazilian breast cancer patients a systematic literature review
Costa, Eduardo Silvestre Vaz; Melazzo, Isabelle Franco; Nogueira, Nathália Amaral; Abreu, Deidimar Cassia; Ayres, Flavio Monteiro; Saddi, Vera Aparecida.
Affiliation
  • Costa, Eduardo Silvestre Vaz; Pontifícia Universidade Católica de Goiás ­ Goiânia (GO), Brazil. Goiânia. BR
  • Melazzo, Isabelle Franco; Pontifícia Universidade Católica de Goiás ­ Goiânia (GO), Brazil. Goiânia. BR
  • Nogueira, Nathália Amaral; Universidade Federal de Goiás ­ Goiânia (GO), Brazil. Goiânia. BR
  • Abreu, Deidimar Cassia; Pontifícia Universidade Católica de Goiás ­ Goiânia (GO), Brazil. Goiânia. BR
  • Ayres, Flavio Monteiro; Universidade Estadual de Goiás ­ Goiânia (GO), Brazil. Goiânia. BR
  • Saddi, Vera Aparecida; Pontifícia Universidade Católica de Goiás ­ Goiânia (GO), Brazil. Goiânia. BR
Mastology (Online) ; 30: 1-8, 2020.
Article de En | LILACS-Express | LILACS | ID: biblio-1100071
Bibliothèque responsable: BR2499.9
ABSTRACT
This study assessed the prevalence and clinical implications of the TP53 p.R337H mutation in Brazilian breast cancer patients through a systematic literature review. The literature review was performed in the PubMed, Scientific Electronic Library Online (SciELO), and Medical Literature Analysis and Retrieval System Online (MEDLINE) databases from 1997 to 2018. We used the keyword "R337H" in the search since it resulted in the largest number of published articles on the subject. Initially, we found 75 articles, and, after reviewing the titles and abstracts, we selected 18 studies investigating the prevalence of the TP53 p.R337H mutation in breast cancer patients and its clinical implications. The reading of the full texts led to the inclusion of seven studies. The studies were carried out in the states of São Paulo, Rio Grande do Sul, Rio de Janeiro, and Bahia. The TP53 p.R337H mutation was detected in 87 (4.8%) of the 1.789 women with breast cancer investigated. The prevalence of the TP53 p.R337H mutation in the selected studies ranged from 0.5 to 8.6%. These findings highlight the recommendation for screening the R337H variant in breast cancer patients in Brazil and suggest the need for new research addressing the clinical and prognostic aspects of breast cancer patients with TP53 p.R337H mutation-positive.
Mots clés

Texte intégral: 1 Indice: LILACS Type d'étude: Guideline / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Pays comme sujet: America do sul / Brasil langue: En Texte intégral: Mastology (Online) Thème du journal: Neoplasias da Mama Année: 2020 Type: Article

Texte intégral: 1 Indice: LILACS Type d'étude: Guideline / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Pays comme sujet: America do sul / Brasil langue: En Texte intégral: Mastology (Online) Thème du journal: Neoplasias da Mama Année: 2020 Type: Article